Synergy Study Confirms Benefits of Lovenox in Management of High-Risk Non-ST-Elevation ACS Patients
March 09 2004 - 10:16AM
PR Newswire (US)
Synergy Study Confirms Benefits of Lovenox in Management of
High-Risk Non-ST-Elevation ACS Patients Findings of UA/NSTEMI Trial
Presented at ACC NEW ORLEANS, March 9 /PRNewswire-FirstCall/ -- The
results of a landmark, 10,027-patient study show thatLovenox(R)
(enoxaparin sodium injection) is as effective as unfractionated
heparin (UFH) in the treatment of high-risk patients with
non-ST-elevation acute coronary syndromes (ACS) undergoing a rapid
invasive strategy. Findings of the SYNERGY trial were presented
today during a Late-Breaking Clinical Trials session at the
American College of Cardiology's Annual Scientific Session 2004.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000501/NYM197 ) "The
results of previous trials provide strong evidence of the
superiority of enoxaparin over unfractionated heparin in medically
managed ACS patients," said Robert Califf, MD, Associate Vice
Chancellor for Clinical Research, Director, Duke Clinical Research
Institute at Duke University Medical Center, Durham, NC, and a lead
investigator of the trial. "Now, data from SYNERGY demonstrate
benefit with enoxaparin in aggressive management of this high-risk
population as well. Physicians should not hesitate to transition
patients to percutaneous coronary intervention while on
enoxaparin." In this patient population, Lovenox was established to
be at least as effective as UFH in the reduction in the incidence
of death or myocardial infarction at 30 days, the primary endpoint
(14.0 percent vs. 14.5 percent, p= NS). Safety in SYNERGY was
assessed by GUSTO and TIMI major bleeding criteria, rate of
transfusions, intracranial hemorrhage (ICH) and bleeding causing
hemodynamic instability. Results showed that the incidence of GUSTO
severe bleeding was 2.9% with Lovenox(R) vs. 2.4% for UFH (p=NS).
Incidence of TIMI non-CABG major bleeding was 2.4% vs. 1.7% (p=
0.025), a statistically significant difference. Incidence of
bleeding was confounded by extensive anticoagulant switching.
Importantly, there was no difference observed in the incidence of
blood transfusions, ICH and abrupt closure. Patients Started and
Continued on Lovenox(R) Had Better Outcomes A secondary analysis of
5,637 patients enrolled in SYNERGY showed that those who began
treatment with Lovenox(R) prior to randomization and continued on
it throughout the course of therapy experienced an 18 percent
relative risk reduction in the incidence of death and myocardial
infarction at 30 days vs. patients who were started and continued
on UFH (12.8% vs. 15.6%, p=0.0029). "Based on these outcomes,
enoxaparin would appear to be a preferred first-line therapy. These
findings suggest that switching anticoagulant agents during an
episode of ACS, including in the cath lab, provides no clinical
benefit and increases bleeding complications," said James J.
Ferguson, MD, Associate Director of Cardiology Research at the
Texas Heart Institute at St. Luke's Episcopal Hospital in Houston,
TX, and a lead investigator of the study. A meta-analysis of all
ACS trials comparing Lovenox to UFH, in a broad spectrum of
patients ranging from conservatively to invasively managed, shows
that Lovenox significantly reduces the incidence of death and MI,
with no significant increase in bleeding complications. SYNERGY
Trial Design The SYNERGY (Superior Yield of the New Strategy of
Enoxaparin, Revascularization & GlYcoprotein IIb/IIIa
Inhibitors) trial was a prospective, randomized, open-label study
evaluating the efficacy and safety of Lovenox(R) versus UFH in
high-risk patients presenting with non-ST-elevation ACS and treated
with an early invasive strategy. SYNERGY was conducted at
approximately 400 investigative sites in the United States, Canada,
Europe and South America. It is the largest trial ever conducted in
unstable angina and non-ST elevation myocardial infarction
(UA/NSTEMI). All patients enrolled in the study received treatment
with Lovenox(R) or UFH and concomitant therapy with oral and
intravenous antiplatelet agents. "These findings show that patients
receiving enoxaparin throughout the course of therapy experienced
significantly better outcomes compared to UFH," said Dr. Califf.
"Given the wealth of prior data showing its benefits in the
management of ACS patients, its newly demonstrated favorable
profile in early invasive patient management, and convenience of
use, enoxaparin can be considered an anticoagulant of choice in
ACS." About Acute Coronary Syndromes Acute coronary syndromes
involve the formation of blood clots in thevessels that supply
blood to the heart, resulting in the reduction of blood flow to the
heart. These conditions include unstable angina, non-Q-wave or
non-ST-elevation myocardial infarctions, and acute myocardial
infarction (AMI), or heart attack. According to the American Heart
Association, more than 12 million Americans alive today have a
history of coronary heart disease (myocardial infarction, angina
pectoris or both). Acute coronary syndromes are commonly treated
with a combination of anticoagulant medications. Very often,
percutaneous coronary intervention (PCI), such as angioplasty, may
be necessary in these patients. While UFH traditionally has been
used to reduce the risk of blood clots, studies such as the ESSENCE
trial have demonstrated the superiority of Lovenox(R) to
unfractionated heparin in managing UA/NSTEMI. Low-molecular-weight
heparins prevent the formation of a blood clot by inhibiting
thrombin, an enzyme present throughout the circulation system.
Antiplatelet drugs are effective in preventing blood clotting by
inhibiting the aggregation of platelets. PCI describes a procedure
used to dilate narrowed arteries to facilitate blood flow in which
a balloon catheter with or without a stent is introduced into the
blocked artery and inflated to widen its diameter, allowing more
blood to flow through. About Lovenox(R) The No. 1-selling
low-molecular-weight heparin in the world, Lovenox(R) was approved
in the United States and Canada in 1993. It has been available in
Europe since 1987 and is known under the brand names Lovenox(R),
Clexane(R) and Klexane(R). Lovenox(R) is the only
low-molecular-weight heparin approved by the FDA for all of the
following indications: * Prophylaxis of deep-vein thrombosis, which
may lead to pulmonary embolism: -- for medical patients who are at
risk for thromboembolic complications due to severely restricted
mobility during acute illness; -- for patients undergoing abdominal
surgery who are at risk for thromboembolic complications; -- for
patients undergoing hip replacement surgery, during and following
hospitalization; -- for patients undergoing knee replacement
surgery. * Prophylaxis of ischemic complications of unstable angina
and non-Q-wave myocardial infarction, when concurrently
administered with aspirin. * Inpatient treatment of acute deep-vein
thrombosis with or without pulmonary embolism, when administered in
conjunction with warfarin sodium. * Outpatient treatment of acute
deep-vein thrombosis without pulmonary embolism when administered
in conjunction with warfarin sodium. IMPORTANT SAFETY INFORMATION
LOVENOX(R) (enoxaparin sodium injection) cannot be used
interchangeably with other low-molecular-weight heparins or
unfractionated heparin, as they differ in their manufacturing
process, molecular weight distribution, anti-Xa and anti-IIa
activities, units, and dosage. When epidural/spinal anesthesia or
spinal puncture is employed, patients anticoagulated or scheduled
to be anticoagulated with low-molecular-weight heparins or
heparinoids are at risk of developing an epidural or spinal
hematoma, which can result in long-term or permanent paralysis. The
risk of these events is increased by the use of postoperative
indwelling epidural catheters or by the concomitant use of drugs
affecting hemostasis. Patients should be frequently monitored for
signs and symptoms of neurological impairment. (See boxed WARNING.)
As with other anticoagulants, use with extreme caution in patients
with conditions that increase the risk of hemorrhage. Dosage
adjustment is recommended in patients with severe renal impairment.
Unless otherwise indicated, agents that may affect hemostasis
should be discontinued prior to LOVENOX(R) therapy. Bleeding can
occur at any site during LOVENOX(R) therapy. An unexplained fall in
hematocrit or blood pressure should lead to a search for a bleeding
site. (See WARNINGS and PRECAUTIONS.) Thrombocytopenia can occur
with LOVENOX(R). In patients with a history of heparin-induced
thrombocytopenia, LOVENOX(R) should be used with extreme caution.
Thrombocytopenia of any degree should be monitored closely. If the
platelet count falls below 100,000/mm3, LOVENOX(R) should be
discontinued. Cases of heparin-induced thrombocytopenia have been
observed in clinical practice. (See WARNINGS.) The use of Lovenox
has not been adequately studied for thromboprophylaxis in pregnant
women with mechanical prosthetic heart valves (See WARNINGS.)
LOVENOX(R) is contraindicated in patients with hypersensitivity to
enoxaparin sodium, heparin, or pork products, and in patients with
active major bleeding. Please see accompanying information or go to
http://www.lovenox.com/ for complete prescribing information,
including boxed WARNING, and additional important information.
About Aventis Aventis is dedicated to treating and preventing
disease by discovering and developing innovative prescription drugs
and human vaccines. In 2003, Aventis generated sales of euro 16.79
billion (US $18.99), invested euro 2.86 billion (US $3.24) in
research and development and employed approximately 69,000 people
in its core business. Aventis corporate headquarters are in
Strasbourg, France. The company's prescription drugs business is
conducted in the U.S. by Aventis Pharmaceuticals Inc., which is
headquartered in Bridgewater, New Jersey. For more information,
please visit: http://www.aventis-us.com/. Statements in this news
release containing projections or estimates of revenues, income,
earnings per share, capital expenditures, capital structure, or
other financial items; plans and objectives relating to future
operations, products, or services; future economic performance; or
assumptions underlying or relating to any such statements, are
forward-looking statements subject to risks and uncertainties.
Actual results could differ materially depending on factors such as
the timing and effects of regulatory actions, the results of
clinical trials, the company's relative success developing and
gaining market acceptance for new products, the outcome of
significant litigation, and the effectiveness of patent protection.
Additional information regarding risks and uncertainties is set
forth in the current Annual Report on Form 20-F of Aventis on file
with the Securities and Exchange Commission and in the current
Annual Report -- "Document de Reference" -- on file with the
"Autorite des marches financiers" in France. Pursuant to Article 7
of the COB Regulation no. 2002-04, this press release was
transmitted to the Autorite des marches financiers before its
release.
http://www.newscom.com/cgi-bin/prnh/20000501/NYM197DATASOURCE:
Aventis Pharmaceuticals CONTACT: Terri Pedone of Aventis
Pharmaceuticals, +1-908-243-6578, , or On-site at ACC -
+1-908-797-4499; or Karen Dombek of MCS Public Relations,
1-800-477-9626, , or On-site at ACC - +1-908-244-6411 Web site:
http://www.aventis-us.com/
Copyright